Brief: Invivyd Announces General Alignment With FDA On EUA Pathway For Prevention, Treatment Of Symptomatic COVID-19
31/05/2024 12:16
May 31 (Reuters) - Invivyd Inc IVVD.O :
* INVIVYD INC - GENERAL ALIGNMENT WITH FDA ON REPEATABLE,
EXPEDIENT EUA PATHWAY FOR PREVENTION AND TREATMENT OF
SYMPTOMATIC COVID-19
* INVIVYD INC - DIRECT CLINICAL COST OF GENERATING SAFETY
AND PK
DATA CONTEMPLATED IN THIS PATHWAY IS ESTIMATED AT $25-40 MILLION
Source text for Eikon: ID:nGNX4GMlDx
Further company coverage: IVVD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invivyd
See all newsBrief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview